(Alliance News) - Stocks in London are set to open higher on Wednesday, following consumer and producer price inflation data from the UK, ahead of CPI data from the US. Read More
(Alliance News) - Pfizer Inc is selling 700 million shares in Haleon PLC, more than halving its remaining stake, according to a statement from JPMorgan Securities on Tuesday. Read More
(Alliance News) - The FTSE 100 traded lower at midday on Friday although the pound stabilised ahead of key US jobs figures. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - Stock prices in London were mostly higher at midday on Monday, with investors mostly awaiting US inflation data in the afternoon. Read More
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm that spun-out of GSK PLC in 2022 - Says it has completed its acquisition of an additional 33% stake in Tianjin TSKF Pharmaceutical Co Ltd, its joint venture in China, bringing its total stake to 88%. The equity interest was acquired from its joint venture partners, Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd for a total of CNY4.47 billion, around GBP500 million. The transaction completed following approval by Da Ren Tang shareholders at the group's extraordinary meeting in November. Haleon now has the option to acquire Da Ren Tang's remaining 12% shareholding in TSKF. The joint venture accounted for around 40% of Haleon's China revenue in financial 2023. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
Haleon PLC - Weybridge, Surrey-based consumer healthcare products - Says Pfizer Inc representative and Non-Executive Director, David Denton, stepped down from Haleon's board on Wednesday following the reduction of Pfizer's stake in Haleon to below 20% and in line with the two firms' relationship agreement. Current Chief Financial Officer of J Sainsbury PLC Blathnaid Bergin will join the Haleon board as non-executive director on February 24. Read More
(Alliance News) - Vodafone Group PLC on Wednesday said the former chief financial officer of drugs maker GSK PLC will join its board as a non-executive director. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
Haleon PLC - Weybridge, Surrey-based consumer healthcare products - Non-Executive Director Alan Stewart buys 33,923 shares at GBP3.68, worth GBP124,999, on Wednesday. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday: Read More
(Alliance News) - Haleon PLC on Thursday noted a small decline in revenue led by Digestive Health, while its Oral Health products enjoyed popularity. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
Futura Medical PLC - Surrey-based sexual health products company - Announces that the next milestone payment of USD5.0 million, due under its agreement with Haleon PLC, has been triggered by Haleon's distribution of online pre-orders and the availability of Eroxon in US retailers. Eroxon is a fast-acting gel used to treat erectile dysfunction, which has been available without a prescription in UK pharmacies since March last year. Futura Medical struck a licensing deal with Haleon for the gel in July 2023, which has led to its availability in the US from October this year. Futura Medical expects to receive the payment from Haleon shortly. Read More
Haleon PLC - Weybridge, Surrey-based consumer healthcare firm spun-out of GSK PLC in 2022 - Announces it has completed an off-market purchase of 60.5 million shares from Pfizer Inc, for an aggregate purchasing price of GBP230 million. It has cancelled 30.2 million shares and 30.4 million will be held as treasury shares. The total number of issued shares by Haleon now stands at 9.08 billion, with voting rights attributed to 9.05 billion. Read More